Focus: antibody-based therapeutics to watch in 2011

According to Janice Reichert (*), as of early November 2011, a total of 25 antibody-based therapeutics in Phase 3 are to watch in 2012:  AMG 386, bapineuzumab, elotuzumab, epratuzumab, factor VIII-Fc, factor IX-Fc, farletuzumab, girentuximab, inotuzumab ozogamicin, itolizumab, mepolizumab, naptumomab estafenatox, necitumumab, obinutuzumab, ocrelizumab, pertuzumab, ramucirumab, reslizumab, sarilumab, secukinumab, solanezumab, tabalumab, trastuzumab emtansine, vedolizumab, zanolimumab

(*) Antibody-based therapeutics to watch in 2011. Janice M. Reichert (Janice.reichert@landesbioscience.com). Landes Bioscience; Austin, TX USA

Free article available at:

http://www.landesbioscience.com/journals/mabs/ReichertMABS4-1.pdf

Antibody-based therapeutics in Phase 3 studies as treatments for cancer indications

International non-proprietary name		Target; description	Indication of Phase 3 study
Naptumomab estafenatox	Fab conjugated to staphylococcal enterotoxin A	5T4; Fab conjugated to staph. enterotoxin A	Advanced renal cell carcinoma
AMG 386	Peptibody composed of a peptide fused with an Fc	Angiopoietin-1 and -2; target-binding peptide fused to Fc of human IgG1	Epithelial ovarian, primary peritoneal or fallopian tube cancers
Girentuximab	Canonical IgG1	Carbonic anhydrase ix; IgG1	Non-metastatic renal cell carcinoma
Elotuzumab	Canonical IgG1	CD2; IgG1	Multiple myeloma
Zanolimumab	Canonical IgG1	CD4; IgG1	Mycosis fungoides or Sezary syndrome
Obinutuzumab	Glyco-engineered mAb	CD20; glyco-engineered IgG1	Chronic lymphocytic leukemia; non-Hodgkin lymphoma; advanced diffuse large B-cell lymphoma
Inotuzumab ozogamicin	Antibody-drug conjugate (ADC)	CD22; IgG1 conjugated to calicheamicin	Relapsed/refractory aggressive non-Hodgkin lymphoma
Necitumumab	Canonical IgG1	EGFR; IgG1	Non-small cell lung cancer
Farletuzumab	Canonical IgG1	Folate receptor α; IgG1	Ovarian cancer; adenocarcinoma of the lung
Trastuzumab emtansine	Antibody-drug conjugate (ADC)	HER2; IgG1 conjugated to DM1	Locally advanced or metastatic breast cancer
Pertuzumab	Canonical IgG1	HER2; IgG1	Metastatic breast cancer
Ramucirumab	Canonical IgG1	VEGFR2; IgG1	Metastatic gastric or gastroesophageal junction adenocarcinoma; breast cancer; non-small cell lung cancer; hepatocellular carcinoma; colorectal cancer

Note: Information current as of October 31, 2011.

Abbreviations: CD, cluster of differentiation; EGFR, epidermal growth factor receptor; Fab, antigen-binding fragment; HER2, human epidermal growth factor receptor; VEGFR2, vascular endothelial cell growth factor receptor 2. International non-proprietary naming convention: -umab, human; -zumab, humanized; -ximab, chimeric; -momab, murine.